1. 

   Evaluating the potential for immune escape: how likely is an antibody to protect against a specific SARS-CoV-2 variant?

   out of 5 stars 

   24 May 2024 | Contributor(s): Allyson Sterling, Erica Lannan, Sandra Porter | doi:10.25334/Q7KG-5V20

   Commercial antibodies to the SARS-CoV-2 spike protein have been successfully used to treat people with COVID-19. Unfortunately, as the SARS-CoV-2 virus evolves, new variants have appeared that can escape some of these antibodies. In fact, many commercial antibodies that received Emergency Use...

2. 

   Using the IEDB to Predict Proteasomal Cleavage Events and T-cell Epitopes

   out of 5 stars 

   17 Dec 2022 | Contributor(s): Miko Mallari, Sheela Vemu, Valerie Carson, Golnar Afshar, Alma Rodriguez Estrada, Clifford Wilson, Sandra Porter | doi:10.25334/ADRK-9S16

   Research experiences provide a valuable view into the world of science and a great way to explore new fields and careers while developing critical thinking skills. The development and maintenance of databases have allowed researchers to accelerate research in many fields, and understanding how to...

3. 

   Evaluating the potential for immune escape: how likely is an antibody to protect against a specific SARS-CoV-2 variant?

   out of 5 stars 

   10 Jun 2022 | Contributor(s): Sandra Porter, Uwe Hilgert, Erica Lannan, Michelle Stieber | doi:10.25334/82D0-AT65

   Commercial antibodies to the SARS-CoV-2 spike protein have been successfully used to treat people with COVID-19. Unfortunately, as the SARS-CoV-2 virus evolves, new variants have appeared that can escape some of these antibodies. In fact, many commercial antibodies that received Emergency Use...

Top 3 shown